Bristol-Myers Squibb (BMY)

Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.

AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.

Stocks wavered after the Fed held rates steady and Alphabet's earnings missed on Search revenue, fueling AI bubble concerns despite strong results from Microsoft and resilient earnings elsewhere.

Bristol Myers Squibb’s third quarter results reflected robust growth in its core portfolio, led by strong commercial execution and momentum across newer prod...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 6.9% year on yea...

Bristol Myers Squibb (NYSE:BMY) raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a series of clinical readouts and manufacturing investments intended to support its next generation of l

Bristol Myers Squibb’s adjusted earnings fell 17%, but the company raised its sales outlook. Here’s why the drop reflects a pipeline refill, and what its newer drugs need to deliver next.

Eight growth medicines now each exceed $1 billion in annual sales.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.9% year on year to $13.07 bil...

Every investment carries some measure of risk. These pose less risk than others that offer similar rewards.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what investors should kno...

The medication, which is being developed with the company's Chinese partner, did very well in a late-stage clinical trial.

Don't overthink it. These are blue chip stocks that have simply gone on sale and would be solid additions to almost any income portfolio.

Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.

The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year.

These stocks pay yields far above the S&P 500's. And they keep raising their dividends.

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

One of these pharma stocks offers more income, but the other offers a safer dividend.

Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.

Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.